Skip to main content
. Author manuscript; available in PMC: 2015 Oct 7.
Published in final edited form as: Chem Soc Rev. 2015 Jun 9;44(17):6258–6286. doi: 10.1039/c4cs00511b

Figure 12.

Figure 12

(a) Targeted delivery of CS-TPP/IL-12 nanomedicine: (a1) Construction of nanomedicine by electrostatic co-assembly of CS, TPP and IL-12; (a2) Evaluation of the metastasis immune response by Hematoxylin-Eosin immunohistochemical staining of hepatic metastasis immunoreactive cells in CRC hepatic metastasis model mice treated with free IL-12 and CS-TPP/IL-12 nanomedicine; (a3) The number and volume (a4) of hepatic metastasis in mice treated with CS-TPP carrier, IL-12 drug, CS-TPP/IL-12 nanomedicine.249 Reproduced with permission from ref. 249, Copyright 2012 Elsevier. (b) MMP-responsive drug delivery of the envelope-type MSN nanomedicine. (b1) Construction and responsive mechanism of nanomedicine: (A) functionalization protocol; (B) constructed nanomedicine; (C) undressing of PASP in response to MMP at a tumour site; (D) RGD-mediated uptake; (E) glutathione-triggered drug release inside the cell; (F) apoptosis of tumour cells. (b2) Undressing/release of the PASP protection layer in the presence of MMP-2 (■) or MMP-2 plus MMP inhibitor (▲).253 Reproduced with permission from ref. 253, Copyright 2013 American Chemical Society.